Riskpilot← Back to searchSign inGet full accessPharmasund Nordic ApS
APSActiveCVR 41686669Præstebrovej 44Wholesale of other food · NACE 4638Est. 2020— employees
Revenue 2024
DKK 64K
EBITDA margin
100.0%
+183% vs 2023
Equity ratio
-24.6%
Financial strength
Net profit 2024
DKK 64K
+183% vs 2023
| Revenue | DKK 64K | — |
| EBITDA | DKK 64K | +183% |
| Net profit | DKK 64K | +183% |
| Total assets | DKK 355K | +60699% |
| Equity | DKK -87K | +42% |
| Employees | — | — |
Legal name
Pharmasund Nordic ApS
CVR number
41686669
Legal form
Anpartsselskab
NACE code
4638 · Wholesale of other food
Founded
17. september 2020
Share capital
DKK 40.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Address
Præstebrovej 44
Email
info@pharmasundnordic.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | — | — | — | 64 |
| Staff expenses | -0 | -0 | -0 | -0 |
| EBITDA | 0 | 0 | -77 | 64 |
| Depreciation & amort. | -0 | -0 | -0 | -0 |
| EBIT | 0 | 0 | -77 | 64 |
| Net financials | 0 | 0 | -0 | -0 |
| Profit before tax | 0 | 0 | -77 | 64 |
| Tax | -0 | -0 | -0 | -0 |
| Net profit | 0 | 0 | -77 | 64 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 62 | 52 | 1 | 355 |
| Equity | 50 | 50 | -151 | -87 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 12 | 2 | 152 | 442 |
| Total debt | 12 | 2 | 152 | 442 |
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
20212024
Equity ratio
-24.6%
This company
38.2%
Market median
-164% vs market
20212024
Return on equity
6392100.0%
This company
18.4%
Market median
+34739574% vs market
20212024
Net profit margin
100.0%
This company
8.1%
Market median
+1135% vs market
20212024
Asset turnover
0.18×
This company
1.12×
Market median
-84% vs market
20212024
Debt / equity
5.06×
This company
0.62×
Market median
-716% vs market
20212024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2020-09-17 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
MJ Founder | Founder | 2020 |
EA Founder | Founder | 2020 |
IN Chief Executive Officer | Chief Executive Officer | 2024 |
| Former (2) | ||
ML Management | Management | 2023 – 2024 |
PA Management | Management | 2020 – 2023 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 33.33–49.99% | 33.33–49.99% | 2023 | |
| Company | 33.33–49.99% | 33.33–49.99% | 2023 | |
| Company | 33.33–49.99% | 33.33–49.99% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
P8 Ventures ApS
Pharmasund Nordic ApS Board members of Pharmasund Nordic ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mette Lund Lavesen | Management | 0 companies |
| Marina Jimenez Camacho | Founder | 0 companies |
| Eman A M Ikhdair | Founder | 0 companies |
| Puyan Abedinpour Farahani | Management | 0 companies |
| Ismail Nayef Ismail Khdeir | Chief Executive Officer | 0 companies |